Stock OCGN OCUGEN, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Ocugen, Inc.

Equities

OCGN

US67577C1053

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-07 pm EDT 		5-day change 1st Jan Change
1.6 USD -7.51% Intraday chart for Ocugen, Inc. -7.51% +178.26%
May. 31 Sector Update: Health Care Stocks Advance Friday Afternoon MT
May. 31 Ocugen Gets Recommendation For Dose Escalation in Eye Disease Trial; Shares Climb MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Sector Update: Health Care Stocks Advance Friday Afternoon
Ocugen Gets Recommendation For Dose Escalation in Eye Disease Trial; Shares Climb
Ocugen, Inc. Announces Positive Outcome of the Data and Safety Monitoring Board Review for its Phase 1/2 ArMaDa Clinical Trial for OCU410
Ramesh Kumar Announces Not to Stand for Re-Election to the Board of Ocugen, Inc
Ocugen Completes Dosing of Second Group in Stargardt Eye Therapy Safety and Efficacy Study
Ocugen Announces Dosing Completion of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST?A Modifier Gene Therapy
Ocugen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Ocugen, Inc. Announces Ocu400 Modifier Gene Therapy Phase 1/2 Data Presentation At Retinal Cell and Gene Therapy Innovation Summit 2024
Ocugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410 --A Modifier Gene Therapy
Ocugen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for Ocu400?Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication
Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial
Sector Update: Health Care Stocks Rise Late Afternoon
Sector Update: Health Care Stocks Rise Friday Afternoon
Ocugen Says Data, Safety Monitoring Board Issues 'Positive' Review of Eye Disease Treatment -- Shares Rise
Ocugen, Inc. Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for Ocu410--A Modifier Gene Therapy-- in Phase 1/2 Armada Study for Geographic Atrophy
Sector Update: Health Care Stocks Slipping in Afternoon Trading
Ocugen to Restate Financial Statements; Shares Tumble
Ocugen Provides Business Update
Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for Ocu410st?A Modifier Gene Therapy?In Gardian Study for Stargardt Disease
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. OCGN Stock
  4. News Ocugen, Inc.
  5. Other languages